Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
41.59%
0%
41.59%
6 Months
36.44%
0%
36.44%
1 Year
42.66%
0%
42.66%
2 Years
50.89%
0%
50.89%
3 Years
53.25%
0%
53.25%
4 Years
85.05%
0%
85.05%
5 Years
22.89%
0%
22.89%
Genfit SA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
6.05%
EBIT Growth (5y)
8.67%
EBIT to Interest (avg)
-3.09
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.34
Sales to Capital Employed (avg)
0.27
Tax Ratio
100.00%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
5.82%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.32
EV to EBIT
-6.39
EV to EBITDA
-6.79
EV to Capital Employed
2.51
EV to Sales
4.83
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-39.22%
ROE (Latest)
-74.43%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Bullish
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'23
Dec'23
Dec'22
Change(%)
Net Sales
28.60
20.20
41.58%
Operating Profit (PBDIT) excl Other Income
-34.90
-31.20
-11.86%
Interest
4.60
4.40
4.55%
Exceptional Items
0.50
0.00
Consolidate Net Profit
-28.90
-23.70
-21.94%
Operating Profit Margin (Excl OI)
-1,279.70%
-1,635.10%
35.54%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2023 is 41.58% vs -74.78% in Dec 2022
Consolidated Net Profit
YoY Growth in year ended Dec 2023 is -21.94% vs -135.22% in Dec 2022
About Genfit SA 
Genfit SA
Pharmaceuticals & Biotechnology
Genfit SA is a France-based biopharmaceutical company that specializes in the development of medicines for the prevention and treatment of diabetes and related disorders. The Company is focused on contributing to bringing medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver, such as Nonalcoholic steatohepatitis (NASH) or the bowel, such as the inflammatory bowel disease. The Company targets a number of therapeutic areas, which includes nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), NASH diagnosis, NASH-induced fibrosis and IL-17 dependent autoimmune diseases. The Company’s research programs develop diversified pipeline of drug candidates, including Elafibranor in NASH, which is in phase III; Elafibranor in PBC, which is in phase II; In-Vitro diagnostic test for NASH and Nitazoxanide in fibrosis, which is still in clinical stage, among others.
Company Coordinates 
Company Details
Parc Eurasante 885 avenue Eugene Avinee , LOOS None : 59120
Registrar Details






